arrow
V

Vennis Hong

Kaiser Permanente Southern California
H指数:26
被引数:4,091

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A modified self-controlled case series on mortality risk following primary series doses of COVID-19 vaccines in U.S. Medicare beneficiaries aged 65 years and older

一项针对美国65岁及以上医疗保险受益人接种新冠疫苗基础免疫剂量后死亡风险的改良自控病例系列研究

Vaccine
IF3.5
2026-03-120
PRE
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus-Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season

老年人呼吸道合胞病毒相关急性呼吸道疾病疫苗有效性估计:基于首次上市后季节的研究结果

2025-10-011
OAAI
A three-part model for the self-controlled case series design to estimate and characterize adverse event risk in an overlapping risk period after multiple vaccines: application to ischemic stroke following Pfizer-BioNTech bivalent COVID-19 vaccine and influenza vaccine

徐, S.; Sy, L.S.; 黄, X.; Hong, V.; 韩, B.; Bruxvoort, K.J.; Lewin, B.; Holmquist, K.J.; 钱L. 一种用于自控病例系列设计的三部分模型,用于估计和描述在重叠风险期后多种疫苗的不良事件风险:应用于辉瑞-BioNTech二价COVID-19疫苗和流感疫苗后的缺血性中风。Am. J. Epidemiol. 2025. [Google Scholar] [CrossRef]

2025-06-040
OAAI
Respiratory syncytial virus vaccine uptake among adults aged ≥60 years in a large, integrated healthcare system in Southern California 2023-2024

南加州大型整合医疗体系中≥60岁成人呼吸道合胞病毒疫苗接种率(2023-2024)

VACCINE
IF3.5
2025-04-010
PRE
Association of Pneumococcal Conjugate Vaccination With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Older Adult Recipients of Coronavirus Disease 2019 Vaccines: A Longitudinal Cohort Study

肺炎球菌结合疫苗接种与冠状病毒病2019疫苗老年接受者新型冠状病毒感染的关联: 一项纵向队列研究

2024-08-050
OAAI
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study

BNT162b2 BA.4/5二价mRNA疫苗对美国大型卫生系统中一系列新型冠状病毒肺炎结果的有效性: 一项测试阴性病例对照研究

2023-12-0123
OAAI